26.12.2021, 2492 Zeichen

Andritz: International technology group Andritz has received a repeat order – now the third order within the past 12 months – from Nine Dragons Paper Industries to supply a complete OCC line to China. Start-up is scheduled for the third quarter of 2023. With the delivery of this FibreFlow drum pulper, ANDRITZ will have supplied more than 30 drum pulpers to Nine Dragons.

AT&S: To supply the medical sector with the most modern technology in the future, AT&S has implemented a comprehensive technology upgrade at the Ansan site in Korea, with which the production technologies in the plant have been raised to a new level. “After this upgrade, around 8,000 square meters of additional production space will be available, most of which will be used for the manufacture of interconnection solutions for medical technology applications. At the same time, our production equipment was also brought up to date”, explains Christian Fleck, COO of the Automotive, Industrial and Medical business unit at AT&S. With the newly installed systems, such as multilayer flex presses, machines for e-copper coating, and highly innovative UV lasers, production capacities will be increased by more than a quarter. On the other hand, the new infrastructure makes a significant contribution to more efficient and resource-saving circuit board production, for example in the area of ​​water treatment.

Valneva: Austrian/French Valneva SE, a specialty vaccine company, today announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination. Juan Carlos Jaramillo, Chief Medical Officer of Valneva commented, “We are extremely pleased with these lot-to-lot Phase 3 data, which come in addition to the compelling pivotal Phase 3 results we reported in August. The lot-to-lot data will be part of our submission with the US Food and Drug Administration (FDA), which we plan to start in 2022. Chikungunya is a major, growing and unmet public health threat, yet no vaccine or specific treatment is currently available to prevent this debilitating disease. We will continue to work assiduously to bring VLA1553 to market as soon as possible.”

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (21/12/2021)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1122: ATX deutlich fester, FACC resilient, Kontron sieht sich günstig und Private Equity vs. Neobroker-Depots

Bildnachweis

Aktien auf dem Radar:Mayr-Melnhof, CPI Europe AG, Semperit, Austriacard Holdings AG, EuroTeleSites AG, Zumtobel, Lenzing, ATX, ATX Prime, ATX TR, voestalpine, Wienerberger, Bajaj Mobility AG, ATX NTR, OMV, Addiko Bank, Andritz, AT&S, Erste Group, Frequentis, Gurktaler AG VZ, Reploid Group AG, RBI, Uniqa, VIG, Athos Immobilien, BKS Bank Stamm, Oberbank AG Stamm, Marinomed Biotech, Amag, CA Immo.

---